We are actively watching for developments in new types of treatments, whether it's treating after diagnosis or prophylactically in advance, such as with Evusheld from AstraZeneca. There's the evolution of monoclonal antibody treatment, which we know varies in effectiveness with the nature of the specific variant. There's the development of new formulations for vaccines that consider the original virus strain as well as variants, such as omicron.
These are important developments that the public health agencies, Health Canada and CIHR, from a regulatory perspective, are tracking to ensure that Canadians can have access, in a timely fashion, to the most effective vaccines and treatments.
Similarly, in terms of—